[ad_1]
(MedPage Today) — A first-line regimen involving pembrolizumab (Keytruda) and olaparib (Lynparza) significantly reduced the risk of disease progression or death in ovarian cancer patients without BRCA mutations, a randomized trial showed.
In…
[ad_2]
Source link : https://www.medpagetoday.com/meetingcoverage/sgo/114711
Author :
Publish date : 2025-03-18 16:19:00
Copyright for syndicated content belongs to the linked Source.
Pembrolizumab-Olaparib Boosts PFS in Non-BRCA Ovarian Cancer
Related Posts
